Last Updated: 30/09/2025
An ultra-short course of Primaquine for the radical cure of vivax malaria
Objectives
This research project proposes a multicentre trial to evaluate the safety and efficacy of an ultra-short, three-day course of primaquine for the radical cure of vivax malaria.
Principal Institution
Principal Investigators / Focal Persons
Rationale and Abstract
Current treatment regimens to prevent relapsing malaria are too long. A shorter higher dose treatment could improve treatment outcomes but this needs to be balanced against increased risk of side effects. Recent data from a trial in children in PNG suggests a shortened treatment of 3 days is safe and effective. This trial is expected to directly influence global treatment policies.
External reference
Date
Jan 2026 — Dec 2029
Total Project Funding
$3.13M
Funding Details
Project Site
Related Resources
